News Releases

News Releases

Date Title
Oct 12, 2021 Sesen Bio Expands CMC and Clinical Teams
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 12, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the expansion of its chemistry, manufacturing, and control (CMC) and clinical
Aug 13, 2021 Sesen Bio Receives Complete Response Letter from FDA for Vicineum™ (oportuzumab monatox-qqrs)
Company to host conference call on Monday, August 16 at 8:00 a.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 13, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it
Aug 11, 2021 Sesen Bio Strengthens Executive Leadership Team as the Company Approaches the Potential Approval and Commercial Launch of Vicineum™
John Knighton to join Sesen Bio as Vice President and Chief Compliance Officer The Company believes it remains on track for an FDA decision on its BLA for Vicineum by August 18, 2021 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 11, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company
Aug 9, 2021 Sesen Bio Reports Second Quarter 2021 Financial Results and Significant Global Progress for Vicineum™
The Company believes it remains on track for an FDA decision on its BLA for Vicineum by August 18, 2021 The Company also believes it remains on track for potential approval in Europe and key markets in MENA in 2022 Strengthened balance sheet with $151M in cash and cash equivalents as of June 30,
Aug 5, 2021 Sesen Bio Announces Partnership with Eczacibasi Pharmaceuticals Marketing (EIP) for the Commercialization of Vicineum™ in Turkey
Sesen Bio to receive $1.5 million upfront and is eligible for additional regulatory and commercial milestone payments Sesen Bio is entitled to receive a 30% royalty on net sales in Turkey CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company
Aug 2, 2021 Sesen Bio Strengthens Leadership Team as the Company Approaches the Potential Approval and Launch of Vicineum™
Company announces hiring of Amy Ponpipom as Vice President, Assistant General Counsel CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 2, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today
Jul 26, 2021 Sesen Bio Announces Significant Commercial Progress as the Company Approaches the Potential Approval and Launch of Vicineum™ in the US
Hiring of the US sales force is 97% complete and sales training has commenced 14 Key Opinion Leader (KOL) speakers have been identified and speaker training has commenced Two-pronged market access and reimbursement strategy has commenced CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul.
Jul 21, 2021 Sesen Bio Announces New Appointments to its Board of Directors
Peter K Honig, MD, MPH and Michael A.S. Jewett , MD, FRCSC, FACS have joined the Sesen Bio Board of Directors as the Company nears potential US approval of Vicineum™ in August 2021 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 21, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company
Jul 20, 2021 Sesen Bio and Qilu Pharmaceutical Announce Enrollment of First Patient in Clinical Trial for Vicineum™ in China
Anticipated submission of product market application for Vicineum in China in 2022, with potential approval in 2023 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 20, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of
Jul 14, 2021 Sesen Bio Announces Productive Late-Cycle Meeting with the FDA for Vicineum™
No Advisory Committee meeting is planned at this time No confirmatory trial required at this time Company believes it remains on track for August 18 th target PDUFA date CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 14, 2021-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted
Displaying 1 - 10 of 31
Top